Academic Journal
333P Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
| العنوان: | 333P Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial |
|---|---|
| المؤلفون: | Cottu, P.H., Ring, A., Marchetti, P., Cardoso, F., Salvador, J., Neven, P., Papazisis, K., Campone, M., Bachelot, T., Menon-Singh, L., Wu, J., Zhou, K., De Laurentiis, M. |
| المساهمون: | Novartis Pharmaceuticals Corporation |
| المصدر: | Annals of Oncology ; volume 31, page S379-S380 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2020 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2020.08.435 |
| الاتاحة: | http://dx.doi.org/10.1016/j.annonc.2020.08.435 https://api.elsevier.com/content/article/PII:S0923753420404314?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0923753420404314?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; http://www.elsevier.com/open-access/userlicense/1.0/ |
| رقم الانضمام: | edsbas.D18D21A2 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2020.08.435 |
|---|